COMMUNIQUÉS West-GlobeNewswire

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
24/10/2026
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus hormone therapy compared with immediate surgery 1 Twice as many patients remained free from [...]
Melbourne coach Dominik Kulewski's Weight Loss Lab clients have now lost about 3 tonnes combined
24/10/2026
Results include a US client who lost 145kg without surgery and a man who lost more than 80kg after being called a lost cause Melbourne, Australia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Clients of Dominik Kulewski, the [...]
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
24/10/2026
Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal [...]
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
24/10/2026
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety [...]
XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux
24/10/2026
AUSTIN, Texas, 24 oct. 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd’hui que son conseil d’administration avait élu Jan-Paul Simard au poste de co-directeur général, aux côtés de la directrice [...]
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
24/10/2026
Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmark Disease control rate of 100% across all response-evaluable patients receiving a starting dose [...]
Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress
24/10/2026
Presented first-in-class clinical proof-of-concept data in KRAS G12D mutant CRC with combination of QTX3034 and anti-EGFR ± chemotherapy Combinations demonstrated robust anti-tumor activity with no new safety signals in [...]
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
24/10/2026
Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases ORR and median duration of [...]
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
24/10/2026
As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or [...]
KFSH élargit l’accès aux urgences grâce aux soins virtuels et à la coordination des spécialistes
24/10/2026
RIYAD, Arabie saoudite, 24 oct. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSH) élargit l’accès des patients à l’expertise des services d’urgence au-delà de ses locaux. Son accès [...]
KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
24/10/2026
RIYADH, Saudi Arabia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is widening patients’ access to emergency expertise beyond its physical departments. Its virtual [...]
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
24/10/2026
ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levels Confirmed objective response rates (cORR) of [...]
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
24/10/2026
IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profile IMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate [...]
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
24/10/2026
ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence Interim analysis [...]
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
24/10/2026
SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
24/10/2026
ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight’s [...]
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
23/10/2026
Study met its primary objective: 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix ® was generally [...]
Beyond Elizabeth Holmes: Ryan El Hosseiny Thanks Nathan Fielder for Shining a Light on Cancer Research
23/10/2026
MIAMI, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Featured as “The Billboard Guy” in Nathan Fielder's documentary, You Can See Everything , biochemist, entrepreneur and Just Blood founder Ryan El Hosseiny welcomes the spotlight [...]
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
23/10/2026
First-in-human data for ARR-217 selected as a late-breaking oral presentation ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN SQUARE, Pa., [...]

Pages